Skip to main content
Premium Trial:

Request an Annual Quote

Cellzome Reels in $5M German Tech Development Grant

NEW YORK (GenomeWeb News) – Cellzome will use a €3.85 million ($5 million) grant it has won from the German government as part of a high-tech funding program to expand its KinoBeads technology application.
The company plans to use the funds specifically to develop the KinoBeads platform for use in epigenetic target classes and to optimize it for diagnostic and translational medicine studies that would allow doctors to monitor target-drug interactions directly in patient material.
Cellzome is working on expanding its proteomics platform so that it may be applied more broadly in drug discovery and development programs for inflammatory diseases and translational medicine.
The five-year grant was awarded by Germany’s HighTech initiative, which is funding technology companies in five regions. Cellzome, which has its German base in Heidelberg, is located in the Rhine-Neckar Region, which received a total of €40 million in grants for biotechnology research in its BioRN cluster. Participants in the BioRN cluster include pharmaceutical companies such as Merck, Serono, and Roche, research institutions, and other biotechnology firms. The company noted that the other four regions landed grants for technologies outside of the life sciences.
In September, Cellzome formed a strategic research alliance with GlaxoSmithKline to discover, develop, and market novel kinase-targeted therapeutics for inflammatory disease. It also is working with Johnson & Johnson to discover novel Alzheimer’s disease treatments.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.